The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil (Cialis – Lilly) for
treatment of signs and symptoms of benign prostatic
hyperplasia (BPH) in men with or without erectile dysfunction.
Tadalafil is approved for use under another brand
name (Adcirca) for treatment of pulmonary arterial hypertension.
The other PDE-5 inhibitors available in the US
for treatment of erectile dysfunction (sildenafil [Viagra];
vardenafil [Levitra]) have also been reported to be effective
for treatment of BPH signs and symptoms, but have
not been approved for this indication by the FDA....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
Information about the article:
Title: Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1377
Article Code: 1377b
Date: November 14, 2011
Volume: 53
Pages: 89-90